Novartis

News

Novartis hits back at Entresto selection on Medicare list

Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations,

News

Novartis gets a win in chronic hives, setting up filings

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a su

News

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in

News

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a

News

TIGIT underwhelms again as Novartis ducks out

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered

News

Novartis will appeal Entresto patent setback

Novartis has suffered a defeat in its legal defence of chronic heart failure therapy Entresto, which accounted for around 11% of its revenues last year, but has vowed to t

Novartis hits back at Entresto selection on Medicare list

Novartis gets a win in chronic hives, setting up filings

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

TIGIT underwhelms again as Novartis ducks out

Novartis will appeal Entresto patent setback

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks